Effects of Repetitive Transcranial Magnetic Stimulation on Cerebral Autoregulation in Patients With Acute Ischemic Stroke
NCT ID: NCT05843240
Last Updated: 2025-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
128 participants
INTERVENTIONAL
2023-05-07
2024-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sensory Cueing on Unilateral Neglect in Subacute Patients With Right Hemispheric Stroke
NCT02645344
Low-frequency Transcranial Magnetic Stimulation To Enhance Motor Recovery In The Subacute Phase After Stroke
NCT01333579
rTMS and Robotic Gait Training in Patients With Stroke
NCT03817385
Individualized rTMS for Motor Recovery in Stroke Patients
NCT05914038
Transcranial Magnetic Stimulation in Stroke Motor Rehabilitation Treatment
NCT03268070
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
rTMS
Patients are treated with repetitive transcranial magnetic stimulation (rTMS).
Repetitive transcranial magnetic stimulation
After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
sham-rTMS
Patients are treated with sham repetitive transcranial magnetic stimulation (sham-rTMS).
Sham repetitive transcranial magnetic stimulation
After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive transcranial magnetic stimulation
After enrollment, patients received rTMS once a day for 5 consecutive days (stimulation plan: stimulation of M1 region on the affected side at 10Hz).
Sham repetitive transcranial magnetic stimulation
After enrollment, patients received sham-rTMS once a day for 5 consecutive days with the same parameters as the rTMS group, but the coil was rotated 90° away from the scalp.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Clinically definite diagnosis of acute ischemic stroke;
3. Baseline National Institute of Health Stroke Scale (NIHSS) score ≤25;
4. Pre-onset modified Rankin Scale (mRS) score ≤1;
5. Randomized and initiated transcranial magnetic stimulation within 1 week of onset;
6. Subject or legal representative agreed to the treatment and signed the informed consent.
Exclusion Criteria
2. Patients with serious physical diseases or who have had craniocerebral surgery;
3. Previous history of epilepsy, family history of epilepsy or presence of seizure provoking factors;
4. Pregnancy or breastfeeding;
5. The presence of metal foreign bodies near the stimulation site, such as intracranial metal implants, cochlear implants, built-in pulse generators (brain pacemakers, cardiac pacemakers), etc.;
6. Patients who are unable to complete cerebral autoregulation, or bilateral temporal window penetration poorly;
7. life expectancy of ≤3 months or inability to complete the study for other reasons;
8. unwillingness to be followed up or poor treatment compliance;
9. Those who are participating in other clinical investigators, or who have participated in other clinical studies within 3 months prior to enrollment, or who have participated in this study;
10. Other conditions that the investigators deemed unsuitable for enrollment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Yi Yang
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yi Yang
Vice President of First Hospital of Jilin University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Hospital of Jilin University
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMSCA-AIS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.